Ultragenyx Pharmaceutical Inc (RARE)
Ultragenyx Pharmaceutical is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Co. has four commercially approved products, Crysvita® (burosumab) for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia, Mepsevii® (vestronidase alfa) for the treatment of mucopolysaccharidosis VII, or Sly Syndrome, Dojolvi® (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders, and Evkeeza® (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
RARE SEC Filing Email Alerts Service
| Company Name: |
Ultragenyx Pharmaceutical Inc |
| Website: |
www.ultragenyx.com |
| Sector: |
Drugs & Pharmaceuticals |
| Number of ETFs Holding RARE: |
40 |
| Total Market Value Held by ETFs: |
$451.86M |
| Total Market Capitalization: |
$3.48B |
| % of Market Cap. Held by ETFs: |
12.97% |
|
|
April 18, 2024 • 9:36 PM Eastern
Strong Buy (3.80 out of 4)
100th percentile
|
|
Free RARE Email Alerts:
